Taisho Pharmaceutical Co., Ltd.

Takahiro Oi

Masato Takahashi

Hiroaki Tanaka

Hiroyuki Kakinuma

Yohei Kobashi

Hitomi Takahashi

Fumiyasu Shiozawa

Kenichi Kawabe

Yuko Hashimoto

Yuki Iwata

Yoshinori Sekiguchi

Tetsuya Yabuuchi

Tetsuo Takayama

Yusuke Oka

Shoichi Kuroda

Tomomichi Chonan

Yoshihisa Shirasaki

Tsuyoshi Shibata

Naoya Ono

Nagaaki Sato

Shigeru Tokita

Hajime Asanuma

Yuki Shimizu

Makoto Hamada

Fumihito Ushiyama

Hideaki Amada

Madoka Kawamura

Fumito Uneuchi

Takeshi Koami

Daisuke Matsuda

Daisuke Wakasugi

Akira Hiratate

Rie Nishikawa

Kanako Iwakiri

Tsuyoshi Busujima

Sota Kato

Chie Koizumi

There are provided compounds having a superior PHD2 inhibitory effect that are represented by general formula (I'): (in the above-mentioned general formula (I&#x2032;),W, Y, R, R, R, and Yare as described hereinabove), or pharmaceutically acceptable salts thereof.

Partially saturated nitrogen-containing heterocyclic compound

A compound, which inhibits SGLT1 (sodium-dependent glucose transporter 1) activity to suppress absorption of glucose or the like, thereby suppressing abnormal glucose tolerance or postprandial hyperglycemia in diabetes, is provided. Specifically, a 4-isopropyl-6-methoxyphenyl glucitol compound represented by the following formula (I), or a pharmaceutically acceptable salt thereof, is provided: 

4-isopropyl-6-methoxyphenyl glucitol compound

There are provided compounds represented by the following general formula (I) or pharmaceutically acceptable salts of thereof, which have a superior monoacylglycerol acyltransferase 2 inhibitory action: wherein wherein

Nitrogen-containing condensed heterocyclic compound

A compound represented by formula (1) or a pharmaceutically acceptable salt thereof, which has a PI3 kinase &#x3b3; inhibitory effect and is useful as a prophylactic or therapeutic agent for articular rheumatism, Crohn's disease, irritable colitis, Sjoegren's syndrome, multiple sclerosis, systemic lupus erythematosus, asthma, atopic dermatitis, arteriosclerosis, organ transplant rejection, cancer, retinopathy, psoriasis, arthrosis deformans, age-related macular degeneration, type II diabetes, insulin resistance, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hyperlipemia, etc.

Aminothiazole derivative

The present invention provides 4-isopropylphenyl glucitol compounds which have no tendency to accumulate in the body and which inhibit SGLT1 activity to suppress postprandial hyperglycemia (or impaired glucose tolerance) through suppression of glucose absorption in the small intestine, whereby the compounds, for example, can suppress the onset of diabetes and metabolic syndrome or can treat these diseases. A 4-isopropylphenyl glucitol compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein Rrepresents a hydrogen atom, etc., Rrepresents a methyl group, etc., Rrepresents a Calkyl group substituted with an amino group(s), etc., and Rrepresents a hydrogen atom, etc.

4-isopropylphenyl glucitol compounds as SGLT1 inhibitors

A compound represented by formula (I) or a pharmaceutically acceptable salt thereof has an effect of inhibiting CRTH2 and, therefore, is useful as a preventive or a remedy for allergic diseases such as asthma, atopic dermatitis and allergic rhinitis.

Isoquinoline derivative

C-phenyl 1-thioglucitol compounds of the following formula (I) or pharmaceutically acceptable salts thereof or hydrates thereof: [wherein

C-phenyl 1-thioglucitol compound

Provided is a novel C-phenyl glycitol compound that may serve as a prophylactic or therapeutic agent for diabetes by inhibiting both SGLT1 activity and SGLT2 activity, thereby exhibiting a glucose absorption suppression action and a urine glucose excretion action. A C-phenyl glycitol compound represented by Formula (I) below or a pharmaceutically acceptable salt thereof or a hydrate thereof  

C-phenyl glycitol compound

The present invention provides a 1-thio-D-glucitol compound of the following formula, which shows the action of inhibiting the activity of SGLT2, a pharmaceutically acceptable salt of the compound, or a hydrate of the compound or the salt; and a pharmaceutical comprising such a compound as an active ingredient, especially, a pharmaceutical for preventing or treating diabetes, diabetes-related disease, or diabetic complication. The invention also provides a method for producing the 1-thio-D-glucitol compound and its intermediate. 

1-thio-D-glucitol derivatives

Growing community of inventors

Toshima-ku, Japan

Takahiro Oi